The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Open accessAbstract
Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the α-subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor α. In preclinical models, down-regulation of HIF-α, especially HIF-2α, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivation of the VHL tumor suppressor gene, which results in pseudo-hypoxic stabilization of both HIF-1α and HIF-2α, is an initiating genetic event for both hereditary (VHL disease) and sporadic ccRCCs [16].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although mTOR and the overall process of HIF-1α protein synthesis are limited under normoxia, it was found that 75% of sporadic clear cell RCCs are VHL-deficient, thus, in this case HIF-1α translation can proceed smoothly serving as a target for mTOR inhibitors intervention58.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation(2000) · PubMed · Cited by 1,445
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234
Cited by
Sorted by citations
Items 101–200 of 336
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M., & Gudas, L. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3983 · Cited by 48
Swanton, C., Larkin, J., Gerlinger, M., Eklund, A. C., Howell, M. T., Stamp, G., Downward, J., Gore, M. E., Futreal, P. A., Escudier, B. J., et al. (2010) · Genome Medicine · doi:10.1186/gm174 · Cited by 45
MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
Schanza, L.-M., Seles, M., Stotz, M., Foßelteder, J., Hutterer, G. C., Pichler, M., & Stiegelbauer, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112495 · Cited by 46
The von Hippel‐Lindau Tumor Suppressor Protein: An Update
Kaelin, W. G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35019-2 · Cited by 45
Self-citationKinase targets in renal-cell carcinomas: reassessing the old and discovering the new
Furge, K. A., MacKeigan, J. P., & Teh, B. T. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70380-8 · Cited by 44
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer
Yuen, J. S. P., Akkaya, E., Wang, Y., Takiguchi, M., Peak, S., Sullivan, M., Protheroe, A. S., & Macaulay, V. M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0101 · Cited by 42
Cohen, P. A., Ko, J. S., Storkus, W. J., Spencer, C. D., Bradley, J. M., Gorman, J. E., McCurry, D., Zorro-Manrique, S., Dominguez, A. L., Pathangey, L. B., et al. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.703745 · Cited by 42
Zakharia, Y., Bhattacharya, A., & Rustum, Y. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24297 · Cited by 44
Clark, P. E., & Cookson, M. S. (2008) · Cancer · doi:10.1002/cncr.23645 · Cited by 43
Murakami, M., Zhao, S., Zhao, Y., CHOWDHURY, N. F., Yu, W., Nishijima, K., Takiguchi, M., Tamaki, N., & Kuge, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1624 · Cited by 41
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma
Dormoy, V., Béraud, C., Lindner, V., Thomas, L., Coquard, C., Barthelmebs, M., Didier Jacqmin, D., Lang, H., & Massfelder, T. (2010) · Oncogene · doi:10.1038/onc.2010.557 · Cited by 39
Hypoxia and cell cycle regulation of the von Hippel–Lindau tumor suppressor
Liu, W., Xin, H., Eckert, D., Brown, J. A., & Gnarra, J. R. (2010) · Oncogene · doi:10.1038/onc.2010.395 · Cited by 40
ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma
Arias‐González, L., Moreno, I., Rubio‐del‐Campo, A., Serrano‐Oviedo, L., Valero, M. L., Esparís-Ogando, A., de la Cruz-Morcillo, M. Á., Melgar–Rojas, P., García‐Cano, J., Cimas, F. J., et al. (2013) · Neoplasia · doi:10.1593/neo.121896 · Cited by 43
Renal Cell Carcinoma: Recent Advances in Genetics and Imaging
Choudhary, S., Sudarshan, S., Choyke, P. L., & Prasad, S. R. (2009) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2009.03.003 · Cited by 39
Familial Renal Cancer: Molecular Genetics and Surgical Management
Barrisford, G. W., Singer, E. A., Rosner, I. L., Linehan, W. M., & Bratslavsky, G. (2011) · International Journal of Surgical Oncology · doi:10.1155/2011/658767 · Cited by 40
Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
Bukowski, R. M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00013 · Cited by 38
Liang Cheng, C., Williamson, S. R., Zhang, S., MacLennan, G. T., Montironi, R., & Antonio Lopez-beltran, B. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.72 · Cited by 38
Genome-wide mapping of Hif-1α binding sites in zebrafish
Greenald, D., Jeyakani, J., Pelster, B., Sealy, I. M., Mathavan, S., & van Eeden, F. J. (2015) · BMC Genomics · doi:10.1186/s12864-015-2169-x · Cited by 42
NK Cell-Based Immunotherapy in Renal Cell Carcinoma
Terrén, I., Orrantia, A., Mikelez-Alonso, I., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2020) · Cancers · doi:10.3390/cancers12020316 · Cited by 40
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma
Bennett, K. L., Campbell, R. A., Ganapathi, S. S., Zhou, M., Rini, B. I., Ganapathi, R. N., Neumann, H. P. H., & Eng, C. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20887 · Cited by 37
Rodríguez‐Vida, A., Strijbos, M. H., & Hutson, T. E. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000013 · Cited by 37
Tavares, T. S., Nanus, D. M., Yang, X. J., & Gudas, L. J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6584 · Cited by 37
Aggelis, V., Craven, R. A., Peng, J., Harnden, P., Cairns, D. A., Maher, E. R., Tonge, R., Selby, P. J., & Banks, R. E. (2009) · PROTEOMICS · doi:10.1002/pmic.200800756 · Cited by 37
Porta, C., Sabbatini, R., Procopio, G., Paglino, C., Galligioni, E., & Ortega, C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.81 · Cited by 36
Familial and Hereditary Renal Cancer Syndromes
Coleman, J. (2008) · Urologic Clinics of North America · doi:10.1016/j.ucl.2008.07.014 · Cited by 36
Murakami, A., Wang, L., Kalhorn, S., Schraml, P., Rathmell, W. K., Tan, A. C., Nemenoff, R. A., Stenmark, K. R., Jiang, B.-H., Reyland, M. E., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2016.89 · Cited by 37
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Lalani, A. A., Heng, D. Y. C., Basappa, N. S., Wood, L. A., Iqbal, N., McLeod, D., Soulières, D., & Kollmannsberger, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221108685 · Cited by 40
Verheul, H. M. W., van Erp, K., Homs, M. Y. V., Yoon, G., van der Groep, P., ROGERS, C. G., Hansel, D. E., Netto, G. J., & Пили, Р. (2009) · Urology · doi:10.1016/j.urology.2009.05.075 · Cited by 36
Chou, M. T.-H., Anthony, J., Bjorge, J. D., & Fujita, D. (2010) · Genes & Cancer · doi:10.1177/1947601910366719 · Cited by 37
Weissinger, D., Tagscherer, K. E., Macher-Göppinger, S., Haferkamp, A., Wagener, N., & Roth, W. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-120 · Cited by 34
The solution structure of the ZnF UBP domain of USP33/VDU1
Allen, M. D., & Bycroft, M. (2007) · Protein Science · doi:10.1110/ps.072967807 · Cited by 34
Dagher, J., Kammerer‐Jacquet, S., Brunot, A., Pladys, A., Patard, J., Bensalah, K., Perrin, C., Verhoest, G., Mosser, J., Lespagnol, A., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.06.001 · Cited by 33
Knaup, K. X., Monti, J., Hackenbeck, T., Jobst‐Schwan, T., Klanke, B., Schietke, R. E., Wacker, I., Behrens, J., Amann, K., Eckardt, K., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22065 · Cited by 33
Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
Tang, P. A., Vickers, M. M., & Heng, D. Y. C. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.003 · Cited by 33
Bohonowych, J. E., Peng, S., Gopal, U., Hance, M. W., Wing, S. B., Argraves, K. M., Lundgren, K., & Isaacs, J. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-520 · Cited by 32
“Clear cell renal cell carcinoma (CCRCC) tumors are highly vascularized and among the most lethal kidney tumors [8].”
Backgroundde Leon, A. D., Pirasteh, A., da Costa, D. N., Kapur, P., Hammers, H. J., Brugarolas, J., & Pedrosa, I. (2019) · Radiographics · doi:10.1148/rg.2019180178 · Cited by 34
Napolitano, L., Manfredi, C., Cirillo, L., Fusco, G. M., Passaro, F., Abate, M., Rocca, R. L., Mastrangelo, F., Spirito, L., Pandolfo, S. D., et al. (2023) · Medicina · doi:10.3390/medicina59040767 · Cited by 32
Features of increased malignancy in eosinophilic clear cell renal cell carcinoma
Nilsson, H., Lindgren, D., Axelson, H., Brueffer, C., Saal, L. H., Lundgren, J., & Johansson, M. (2020) · The Journal of Pathology · doi:10.1002/path.5532 · Cited by 32
Recent Progress in Mouse Models for Tumor Suppressor Genes and its Implications in Human Cancer
Inoue, K., Fry, E. A., & Taneja, P. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10358 · Cited by 30
Biology of Metastatic Renal Cell Carcinoma
Milella, M., & Felici, A. (2011) · Journal of Cancer · doi:10.7150/jca.2.369 · Cited by 30
A Zebrafish Model for VHL and Hypoxia Signaling
van Rooijen, E., Santhakumar, K., Logister, I., Voest, E. E., Schulte‐Merker, S., Giles, R. H., & Eeden, F. V. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-381320-6.00007-2 · Cited by 31
Tumor suppressor interactions with microtubules: keeping cell polarity and cell division on track
Hernández, P., & Tirnauer, J. S. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004507 · Cited by 31
Epithelioid angiomyolipoma of the kidney
Kato, I., Inayama, Y., Yamanaka, S., Ohshiro, H., Gomi, K., Shirai, S., Aoki, I., Uemura, H., Miyoshi, Y., Kubota, Y., et al. (2008) · Pathology International · doi:10.1111/j.1440-1827.2008.02322.x · Cited by 29
Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma
Lv, D., Zhao, W., Dong, D., Qian, X., Zhang, Y., Tian, X., & Zhang, J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.021 · Cited by 29
Fisher, R. A., Larkin, J., & Swanton, C. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0137-3 · Cited by 28
Bouillez, A., Gnemmi, V., Gaudelot, K., Hémon, B., Ringot-Destrez, B., Pottier, N., Glowacki, F., Butruille, C., Cauffiez, C., Hamdane, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1768 · Cited by 28
AKT as locus of cancer angiogenic robustness and fragility
Radisavljevic, Z. M. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24115 · Cited by 28
PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials
Vamecq, J., Colet, J., Eynde, J. J. V., Briand, G., Porchet, N., & Rocchi, S. (2012) · PPAR Research · doi:10.1155/2012/304760 · Cited by 28
Cytoreductive nephrectomy in the era of targeted therapies: a review
Pindoria, N., Raison, N. T. J., Blecher, G. A., Catterwell, R., & Prokar Dasgupta, A. (2017) · British Journal of Urology · doi:10.1111/bju.13860 · Cited by 28
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
Mahalingam, D., Espitia, C. M., Medina, E. C., Esquivel, J., Kelly, K. R., Bearss, D. J., Choy, G. S., Taverna, P., Carew, J. S., Giles, F. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.426 · Cited by 27
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 26
Hypoxia‐Inducible Factor‐1 as a Therapeutic Target in Endometrial Cancer Management
Seeber, L. M. S., Zweemer, R. P., Verheijen, R. H. M., & van Diest, P. J. (2010) · Obstetrics and Gynecology International · doi:10.1155/2010/580971 · Cited by 27
Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma
Escudier, B. J., Cosaert, J. G. C. E., & Pisa, P. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1545 · Cited by 27
Prognostic and predictive biomarkers in renal cell carcinoma
Vickers, M. M., & Heng, D. Y. C. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0143-8 · Cited by 27
Carew, J. S., Espitia, C. M., Zhao, W., Mita, M. M., Mita, A. C., & Nawrocki, S. T. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1036 · Cited by 26
Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3029 · Cited by 25
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures
Giovannantonio, M. D., Hartley, F., Elshenawy, B., Barberis, A., Hudson, D., Shafique, H. S., Allott, V. E. S., Harris, D. A., Lord, S., Haider, S. A., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100764 · Cited by 30
Hwang, H. J., Hong, S. H., Moon, H. S., Yoon, Y. E., & Park, S. Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-20075-0 · Cited by 26
Kidney Cancer Pathology in the New Context of Targeted Therapy
Allory, Y., Culine, S., & TAILLE, A. D. L. (2011) · Pathobiology · doi:10.1159/000315543 · Cited by 25
Fisher, R. A., Larkin, J., & Swanton, C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00049 · Cited by 25
Williams, E., Villar‐Prados, A., Bowser, J. L., Broaddus, R. R., & Gladden, A. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189081 · Cited by 25
Chen, Y., Chen, C., Polci, R., Wei, R. L.-H., Riley, D. J., & Chen, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2005 · Cited by 25
Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome
Fu, L., Minton, D. R., Zhang, T., Nanus, D. M., & Gudas, L. J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0423 · Cited by 24
Tuberous sclerosis—A model for tumour growth
Dodd, K. M., & Dunlop, E. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.025 · Cited by 23
Carew, J. S., Esquivel, J., Espitia, C. M., Schultes, C. M., Mülbaier, M., Lewis, J., Janssen, B., Giles, F. J., & Nawrocki, S. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031120 · Cited by 24
Consequences of VHL Loss on Global DNA Methylome
Robinson, C. M., Lefebvre, F., Poon, B. P., Bousard, A., Fan, X., Lathrop, M., Tost, J., Kim, W. Y., Riazalhosseini, Y., & Ohh, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-21524-5 · Cited by 21
Transient receptor potential canonical type 3 channels and blood pressure in humans
Thilo, F., Baumunk, D., Krause, H., Schrader, M. G., Miller, K., Loddenkemper, C., Zakrzewicz, A., Krueger, K., Zidek, W., & Tepel, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832a5a9f · Cited by 21
Ji, Q., & Burk, R. D. (2008) · Biochemistry and Cell Biology · doi:10.1139/o08-035 · Cited by 21
MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma
Shi, L., Wang, M., Li, H., & You, P. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330881 · Cited by 20
New Insights into the Management of Renal Cell Cancer
Pécuchet, N., Fournier, L. S., & Oudard, S. M. (2012) · Oncology · doi:10.1159/000342962 · Cited by 19
Yang, F., Li, H., Ma, X., Gao, Y., Bao, X., Du, Q., Ma, M.-H., Liu, K., Yao, Y., Huang, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7807 · Cited by 19
HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis
Messai, Y., Noman, M. Z., Hasmim, M., Escudier, B. J., & Chouaı̈b, S. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985951 · Cited by 19
Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing
Lin, P., Huang, C., Yu, K., Kan, H.-C., Liu, C., Chuang, C., Lu, Y., Chang, Y., Shao, I., & Pang, S. (2021) · Oncology Letters · doi:10.3892/ol.2021.12430 · Cited by 17
Single-Molecule SERS Discrimination of Proline from Hydroxyproline Assisted by a Deep Learning Model
Zhao, Y., Zhan, K., Xin, P.-L., Chen, Z., Li, S., Angelis, F. D., & Huang, J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c01177 · Cited by 18
Prise en charge et traitements médicaux des cancers du rein en 2010
Albouy, B., Goupil, M. G., Escudier, B. J., & Massard, C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1067 · Cited by 18
Vilaseca, A., Nguyen, D. P., Vertosick, E., Corradi, R. B., Musquera, M., Pérez, M., Fossati, N., Sjoberg, D. D., Farré, R., Almendros, I., et al. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1830-6 · Cited by 17
Li, S., & Xu, W. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29511 · Cited by 18
Kim, K. H., Lee, H. H., Yoon, Y. E., Na, J. C., Kim, S. Y., Cho, Y. I., Hong, S. J., & Han, W. K. (2017) · Oncotarget · doi:10.18632/oncotarget.23087 · Cited by 17
Genitourinary Oncology: Current Status and Future Challenges
Bukowski, R. M. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00032 · Cited by 17
Shoji, S., Nakano, M., Sato, H., Tang, X. Y., Osamura, Y. R., Terachi, T., Uchida, Τ., & Takeya, K. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9612-7 · Cited by 17
Alpers, C. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50025-0 · Cited by 17
Kurban, G., Gallie, B. L., Leveridge, M., Evans, A. J., Rushlow, D., Matevski, D., Gupta, R., Finelli, A., & Jewett, M. A. S. (2011) · Pathology - Research and Practice · doi:10.1016/j.prp.2011.11.001 · Cited by 17
Carmichael, E., Bosco, P. J., Reme, A.-I. S., Ortiz, Y. Y., Ramos, D. A., Gomez, K., Nguyen, B.-N. H., Bornak, A., Liu, Z.-J., & Velazquez, O. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211236 · Cited by 20
Krüse, V., Somers, A., Bortel, L. M. V., Both, A., Belle, S. V., & Rottey, S. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12134 · Cited by 16
Yan, H., Zhu, L., Zhang, J., & Lin, Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00682-y · Cited by 17
Principe, D. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-15714-5 · Cited by 17
Transgenic Models to Understand Hypoxia‐Inducible Factor Function
Doedens, A. L., & Johnson, R. S. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35005-2 · Cited by 16
Acyldepsipeptides inhibit the growth of renal cancer cells through G1 phase cell cycle arrest
Xu, S., Guo, P., Gao, Y., Shi, Q., He, D., Gao, Y., & Zhang, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.119 · Cited by 16
Normoxic destabilization of ATF‐4 depends on proteasomal degradation
Wottawa, M., Köditz, J., & Katschinski, D. M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.02060.x · Cited by 16
Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies
Xiao, C., Liu, S., Ge, G., Jiang, H., Wang, L., Chen, Q., Jin, C., Mo, J., Li, J., Wang, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1086813 · Cited by 16
Update on the Biology and Management of Renal Cell Carcinoma
Dutcher, J. P. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000918 · Cited by 15
Sheng, X., Yan, X., Chi, Z., Cui, C., Si, L., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102755 · Cited by 15
Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on
Samlowski, W. E., Wong, B. Y., & Vogelzang, N. J. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07670.x · Cited by 15
Varghese, B. A., Cen, S., Zahoor, H., Siddiqui, I., Aron, M., Sali, A., Rhie, S. K., Lei, X., Rivas, M., Liu, D. H., et al. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100440 · Cited by 14
Wang, H., Xu, D., Huang, H., Cui, Y., Li, C., Zhang, C., Guo, S., Zhang, L., Xu, X., Xu, J., et al. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9189 · Cited by 14
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Escudier, B. J. (2008) · Biologics · doi:10.2147/btt.s3509 · Cited by 14
Fujita, N., Okegawa, T., Terado, Y., Tambo, M., Higashihara, E., & Nutahara, K. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-369 · Cited by 14
Kim, Y. J., Park, S. J., Kim, N. R., & Chin, H. S. (2017) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2017.31.1.80 · Cited by 14
Li, X., Hou, G., Zhu, Z. G., Yan, F., Wang, F., Wei, D., Zheng, Y., Yuan, J., Zheng, W., Zhang, G., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00839-8 · Cited by 14
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Clinical Cancer Research
- Published
- 2007-01-15
- Volume
- 13
- Issue
- 2
- Pages
- 680s-684s
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2131473358
- Semantic Scholar
- b1ecaaf13be1baca02f75edb325c7d80e991f9a6
- Cited by
- 336
- References
- 80
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 18 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- von Hippel-Lindau protein, VHL tumor suppressor, clear cell renal cell carcinoma, hypoxia-inducible factor, HIF-2α, HIF-1α, ubiquitin ligase, vascular endothelial growth factor, platelet-derived growth factor B, transforming growth factor-alpha, VEGF inhibitors, von Hippel-Lindau disease
- MeSH terms
- Carcinoma, Renal Cell, Genotype, Humans, Kidney Neoplasms, Mutation, RNA, Messenger, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Dimerization, Vascular Endothelial Growth Factor A, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
